摘要
目的探究甲氨蝶呤联合米非司酮治疗剖宫产术后子宫瘢痕妊娠的效果。方法选取2018年1月至2020年1月扬州市妇幼保健院收治的80例剖宫产术后子宫瘢痕妊娠患者,按照随机数字表法分成观察组和对照组,各40例。对照组患者采用甲氨蝶呤治疗,观察组患者采用甲氨蝶呤联合米非司酮治疗,探究两组患者的治疗效果、治疗前后血人绒毛膜促性腺激素(β-HCG)值、妊娠包块尺寸、血β-HCG值恢复正常时间、住院时间和不良反应情况。结果观察组患者的治疗效果优于对照组(P<0.05);观察组患者治疗后的血β-HCG值、妊娠包块尺寸显著优于对照组(P<0.05);观察组患者出现不良反应情况少于对照组(P<0.05);观察组患者血β-HCG值恢复正常时间和住院时间短于对照组(P<0.05)。结论甲氨蝶呤联合米非司酮治疗剖宫产术后子宫瘢痕妊娠效果显著,能显著提高治疗有效率,改善患者血β-HCG值、妊娠包块尺寸水平,减少患者不良反应情况的出现,安全性较高,值得临床推广使用。
Objective To explore the effect of methotrexate combined with mifepristone on uterine scar pregnancy after cesarean section.Methods From January 2018 to January 2020,80 patients with uterine scar pregnancy after cesarean section admitted to Yangzhou Maternal and Child Health Hospital were selected and divided into observation group and control group according to the random number table method.40 patients in the control group were treated with methotrexate,and 40 patients in the observation group were treated with methotrexate combined with mifepristone.The treatment effect of the two groups of patients was explored,and the blood β-HCG before and after treatment,pregnancy mass size,blood β-HCG value return to normal time,hospital stay and adverse reactions was explored.Results The treatment effect of the observation group was better than that of the control group(P<0.05);the blood β-HCC value and pregnancy masses size of the observation group after treatment were significantly better than the control group(P<0.05);the adverse reactions of observation group was less than that of the control group(P<0.05);the time for the blood β-HCG value to return to normal and the hospital stay of the observation group were shorter than those of the control group(P<0.05).Conclusion Methotrexate combined with mifepristone is effective in treating uterine scar pregnancy after cesarean section.It can significantly improve the effective rate of treatment,improve the patient’s blood β-HCG value and the size of pregnancy masses,and reduce the appearance of adverse reactions in patients,and has high security.It is worthy of clinical application.
作者
魏岚
韦玲
WEI Lan;WEI Ling(Yangzhou Maternal and Child Health Hospital,Yangzhou,Jiangsu 225001,China)
出处
《大医生》
2020年第24期51-53,共3页
Doctor